Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interim Buprenorphine Treatment (IBT) for Opioid Dependence
NCT02360007Phase 2Completed
- Sponsor
- University of Vermont Medical Center
- Start
- Jan 2015
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of buprenorphine in opioid use disorder (OUD) (2 arms), sponsored by University of Vermont Medical Center. Primary endpoint: Illicit opioid abstinence at 12 weeks. Started Jan 2015; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02360007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360007.